107 related articles for article (PubMed ID: 19962292)
21. Comparison of the usage of intravenous iloprost and nitroglycerin for pulmonary hypertension during valvular heart surgery.
Baysal A; Bilsel S; Bulbul OG; Kayacioglu I; Idiz M; Yekeler I
Heart Surg Forum; 2006; 9(1):E536-42. PubMed ID: 16387672
[TBL] [Abstract][Full Text] [Related]
22. Effects of inhaled nitric oxide following lung transplantation.
Yerebakan C; Ugurlucan M; Bayraktar S; Bethea BT; Conte JV
J Card Surg; 2009; 24(3):269-74. PubMed ID: 19438780
[TBL] [Abstract][Full Text] [Related]
23. Inhaled nitric oxide potentiates actions of adenosine but not of sodium nitroprusside in experimental pulmonary hypertension.
Patterson KW; Deb B; Kavanagh BP; Pearl RG
Pharmacology; 1999 May; 58(5):246-51. PubMed ID: 10087465
[TBL] [Abstract][Full Text] [Related]
24. Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial.
Sadiq HF; Mantych G; Benawra RS; Devaskar UP; Hocker JR
J Perinatol; 2003 Mar; 23(2):98-103. PubMed ID: 12673257
[TBL] [Abstract][Full Text] [Related]
25. Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension.
Decoene C; Bourzoufi K; Moreau D; Narducci F; Crepin F; Krivosic-Horber R
Can J Anaesth; 2001 Jun; 48(6):584-7. PubMed ID: 11444454
[TBL] [Abstract][Full Text] [Related]
26. Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan-type procedure: a prospective, randomized study.
Cai J; Su Z; Shi Z; Zhou Y; Xu Z; Xu Z; Yang Y
Ann Thorac Surg; 2008 Sep; 86(3):882-8; discussion 882-8. PubMed ID: 18721577
[TBL] [Abstract][Full Text] [Related]
27. Inhaled nitric oxide: effects on hemodynamics, myocardial contractility, and regional blood flow in dogs with mechanically induced pulmonary artery hypertension.
Girard C; Fargnoli JM; Godin-Ribuot D; Dutheil V; Maitrasse B; Girardet P; Arvieux CC
J Heart Lung Transplant; 1996 Jul; 15(7):700-8. PubMed ID: 8820786
[TBL] [Abstract][Full Text] [Related]
28. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up.
Clark RH; Huckaby JL; Kueser TJ; Walker MW; Southgate WM; Perez JA; Roy BJ; Keszler M;
J Perinatol; 2003 Jun; 23(4):300-3. PubMed ID: 12774137
[TBL] [Abstract][Full Text] [Related]
29. Long-term inhaled nitric oxide plus dipyridamole for pulmonary arterial hypertension.
Pérez-Peñate G; Cabrera Navarro P; Ponce González M; Górriz Gómez E; Pulido Duque J; García Quintana A; Juliá Serdá G
Respiration; 2005; 72(4):419-22. PubMed ID: 16088287
[TBL] [Abstract][Full Text] [Related]
30. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.
Preston IR; Klinger JR; Landzberg MJ; Houtchens J; Nelson D; Hill NS
Chest; 2001 Sep; 120(3):866-72. PubMed ID: 11555522
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers.
Zuo XR; Zhang R; Jiang X; Li XL; Zong F; Xie WP; Wang H; Jing ZC
Am J Cardiol; 2012 Jun; 109(12):1801-6. PubMed ID: 22459309
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension.
Morales-Blanhir J; Santos S; de Jover L; Sala E; Paré C; Roca J; Rodriguez-Roisin R; Barberà JA
Respir Med; 2004 Mar; 98(3):225-34. PubMed ID: 15002758
[TBL] [Abstract][Full Text] [Related]
33. Inhaled nitric oxide improves transpulmonary blood flow and clinical outcomes after prolonged cardiac arrest: a large animal study.
Derwall M; Ebeling A; Nolte KW; Weis J; Rossaint R; Ichinose F; Nix C; Fries M; Brücken A
Crit Care; 2015 Sep; 19(1):328. PubMed ID: 26369409
[TBL] [Abstract][Full Text] [Related]
34. Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension.
Barst RJ; Agnoletti G; Fraisse A; Baldassarre J; Wessel DL;
Pediatr Cardiol; 2010 Jul; 31(5):598-606. PubMed ID: 20405117
[TBL] [Abstract][Full Text] [Related]
35. Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension.
Sandqvist A; Henrohn D; Egeröd H; Hedeland M; Wernroth L; Bondesson U; Schneede J; Wikström G
Eur J Clin Pharmacol; 2015 Oct; 71(10):1165-73. PubMed ID: 26242227
[TBL] [Abstract][Full Text] [Related]
36. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.
Budts W; Van Pelt N; Gillyns H; Gewillig M; Van De Werf F; Janssens S
Heart; 2001 Nov; 86(5):553-8. PubMed ID: 11602551
[TBL] [Abstract][Full Text] [Related]
37. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.
Ricciardi MJ; Knight BP; Martinez FJ; Rubenfire M
J Am Coll Cardiol; 1998 Oct; 32(4):1068-73. PubMed ID: 9768734
[TBL] [Abstract][Full Text] [Related]
38. Inhaled nitric oxide and pulmonary vascular resistance.
Bigatello LM; Hurford WE
Crit Care Med; 1999 Sep; 27(9):2060-1. PubMed ID: 10507659
[No Abstract] [Full Text] [Related]
39. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry.
Douwes JM; Humpl T; Bonnet D; Beghetti M; Ivy DD; Berger RM;
J Am Coll Cardiol; 2016 Mar; 67(11):1312-23. PubMed ID: 26988953
[TBL] [Abstract][Full Text] [Related]
40. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension.
Maron BA; Bhatt DL; Nykiel M; Kinlay S; Waxman AB
Crit Pathw Cardiol; 2012 Mar; 11(1):40-2. PubMed ID: 22337220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
